Johnson & Johnson (NYSE:JNJ) Stock Holdings Boosted by Notis McConarty Edward

Notis McConarty Edward raised its stake in Johnson & Johnson (NYSE:JNJ) by 0.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 52,716 shares of the company’s stock after purchasing an additional 75 shares during the period. Johnson & Johnson accounts for about 3.2% of Notis McConarty Edward’s holdings, making the stock its 8th biggest position. Notis McConarty Edward’s holdings in Johnson & Johnson were worth $8,171,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. GW&K Investment Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $35,000. Dark Forest Capital Management LP grew its position in shares of Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after acquiring an additional 188 shares during the last quarter. Ruedi Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $42,000. Kepos Capital LP purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $45,000. Finally, 25 LLC purchased a new position in shares of Johnson & Johnson during the first quarter worth approximately $55,000. 67.57% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.4 %

NYSE:JNJ opened at $166.25 on Friday. The company has a market capitalization of $432.08 billion, a PE ratio of 33.65, a price-to-earnings-growth ratio of 2.77 and a beta of 0.54. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The stock has a fifty day simple moving average of $166.68 and a 200-day simple moving average of $161.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.59 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.86%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 22nd. Citigroup began coverage on Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price target for the company. Barclays increased their price target on Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a report on Monday, July 24th. JPMorgan Chase & Co. increased their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Finally, TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Eight equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $171.80.

Insider Buying and Selling

In related news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.